Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Transcranial Direct Current Stimulation and Language Therapy for Primary Progressive Aphasia

Start: October 10, 2018
End: March 2022
Enrollment: 50

What Is This Study About?

Primary progressive aphasia (PPA) is a neurodegenerative disease that is characterized by the gradual loss of language functioning. This study will test the effects of multiple consecutive transcranial direct current stimulation (tDCS) sessions paired with language therapy in adults with PPA. tDCS is a noninvasive therapy that delivers electrical current to the brain. Participants will initially undergo either active or sham stimulation during a 45-minute oral and written speech-language therapy session. After a two-month washout period, participants will undergo the treatment that they previously didn't receive. Researchers will investigate whether combining the two interventions will enhance word retrieval deficits in PPA and slow the loss of language functioning.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 100 Years

Must have:

  • Diagnosis of PPA
  • Capable of giving informed consent or indicating another to provide informed consent

Must NOT have:

  • Did not speak English before the age of 5
  • Less than 10 years of education
  • Severe naming deficits
  • Significant history of drug or alcohol abuse
  • History of psychiatric or neurological problems affecting the brain (besides PPA)
  • Seizures during the past 12 months
  • History of brain surgery or metal in the head
  • Uncorrected visual loss or hearing loss by self-report
  • Use of medications that lower the seizure threshold (e.g., methylphenidate) or use of N-Methyl-D-aspartate receptor antagonists (e.g., memantine)
  • Scalp sensitivity

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Johns Hopkins University

Source: ClinicalTrials.gov ID: NCT03728582

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health